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Abstract
Background: Zinc treatment shortens diarrhea episodes and can prevent future episodes. In rural Africa, most children with
diarrhea are not brought to health facilities. In a village-randomized trial in rural Kenya, we assessed if zinc treatment might
have a community-level preventive effect on diarrhea incidence if available at home versus only at health facilities.
Methods: We randomized 16 Kenyan villages (1,903 eligible children) to receive a 10-day course of zinc and two oral
rehydration solution (ORS) sachets every two months at home and 17 villages (2,241 eligible children) to receive ORS at
home, but zinc at the health–facility only. Children’s caretakers were educated in zinc/ORS use by village workers, both
unblinded to intervention arm. We evaluated whether incidence of diarrhea and acute lower respiratory illness (ALRI)
reported at biweekly home visits and presenting to clinic were lower in zinc villages, using poisson regression adjusting for
baseline disease rates, distance to clinic, and children’s age.
Results: There were no differences between village groups in diarrhea incidence either reported at the home or presenting
to clinic. In zinc villages (1,440 children analyzed), 61.2% of diarrheal episodes were treated with zinc, compared to 5.4% in
comparison villages (1,584 children analyzed, p,0.0001). There were no differences in ORS use between zinc (59.6%) and
comparison villages (58.8%). Among children with fever or cough without diarrhea, zinc use was low (,0.5%). There was a
lower incidence of reported ALRI in zinc villages (adjusted RR 0.68, 95% CI 0.46–0.99), but not presenting at clinic.
Conclusions: In this study, home zinc use to treat diarrhea did not decrease disease rates in the community. However, with
proper training, availability of zinc at home could lead to more episodes of pediatric diarrhea being treated with zinc in
parts of rural Africa where healthcare utilization is low.
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Introduction
Diarrhea caused approximately 700,000 deaths in children in
2011, mostly in countries where children are deficient in zinc, an
essential trace element for optimal immune response to infections.
[1–4] Zinc treatment of a diarrheal episode has been shown to
decrease the duration and lessen the severity of that diarrhea
episode. [1,5,6] In addition, zinc given for 10–14 days during or
shortly after a diarrheal episode has been shown to decrease
subsequent diarrhea and acute lower respiratory illness infections
over the ensuing few months. [2,7,8] Based on the weight of
available evidence, WHO and UNICEF recommend zinc as an
adjunct for diarrhea treatment for children in developing
countries, and promote zinc use in the recently published
integrated Global Action Plan for Pneumonia and Diarrhoea
(GAPPD). [6,9].
Scaling up the use of zinc in developing countries has been
challenging, due to obstacles of supply, cost, distribution and
training. [10,11] Within the public sector, the initial push has been
to make zinc available in health-facilities. Yet, many children with
diarrhea in developing countries never present to public sector
health-facilities, due to constraints of time, distance and cost of
transport. [12,13] Distribution of zinc through community health
workers (CHWs) has had positive results in several sites in South
Asia and Africa. [7,8,14] There are parts of Africa, though, where
CHWs do not treat illness in the community. Given the evidence
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of zinc’s prevention of diarrhea and respiratory illness, we
investigated whether providing zinc at home for future treatment
of diarrhea had a preventative impact at the community level on
the reduction of diarrhea incidence. As secondary objectives, we
evaluated if availability of zinc in the home had a preventative
impact at the community level on the reduction of respiratory
disease incidence and would result in more diarrhea episodes
being treated with zinc than having zinc available in the clinic
only. We used a village-randomized design to facilitate training,
distribution, and equity among caretakers within a village.
Methods
The protocol and consent forms were reviewed and approved
by the Ethical Review Boards of KEMRI (# 932 and 985) and
CDC (# 4566 and 4678). Written informed consent was obtained
from children’s primary caretakers. The study was registered with
ClinicalTrials.gov (#NCT00530829). The protocol for this trial
and supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Surveillance Platform
Population-based infectious disease surveillance (PBIDS) has
been ongoing since late 2006 in Asembo, western Kenya. [15] On
July 1, 2008, PBIDS included 3,856 children ,5 years of age, in
33 villages. Malaria transmission is endemic and occurs year-
round. [16] The under-5 mortality ratio was 212 per 1,000 live
births in 2008. [17].
The methods for PBIDS have been described. [15,18] In brief,
community interviewers visit enrolled households every two weeks
to inquire about illnesses, referred to as household morbidity
surveillance (HMS). For key symptoms, including cough, fever and
diarrhea, participants provide number of days during the past two
weeks when they had those symptoms. Health-care seeking,
hospital admission, and medication use are also documented. For
children ,5 years, the mother, or other knowledgeable caretaker,
is interviewed. Abbreviated physical exams are done.
In Lwak Hospital, the centrally-located referral facility for
PBIDS, medical care is free to PBIDS participants. Patients are
examined and diagnosed by clinical officers (similar to physician’s
assistants). Malaria blood smears are done on all febrile patients.
Structured questionnaires record symptoms, vital signs, physical
exam findings, diagnosis, and treatment. All children with diarrhea
presenting to Lwak Hospital during the study were given zinc, if
they were not already taking it for the episode, as standard
protocol. We have previously shown that of children in PBIDS
with diarrhea who are brought to a clinic, half are brought to
Lwak Hospital. [19].
Zinc Study Design
The primary objective was to assess if home zinc availability led
to decreased diarrhea incidence in the community. Secondary
objectives were if home zinc availability led to decreased
respiratory infections in the community, and if more children
with diarrhea were treated with zinc when available in the home.
For the zinc study, all residents in the 33 PBIDS villages aged 2–59
months of age on December 1, 2007 were identified. Among these,
only participants enrolled in PBIDS and found at home after three
attempts were eligible for enrollment. Enrollment was rolling until
January 2009, whereby children born after the start of the zinc
study or who in-migrated were eligible after they reached 2
months of age, whereas children reaching their 5th birthday were
excluded. The 33 villages were randomly assigned to receive a 10-
day blister pack of 20 mg dispersible zinc-sulfate tablets (Nutriset,
France) at home every two months (hereafter referred to as ‘‘zinc
villages’’) or to receive no zinc at home, but were told they could
obtain it at Lwak Hospital if their child had diarrhea (hereafter
referred to as ‘‘comparison villages’’). All study participants,
regardless of village category, presenting to Lwak clinic with
diarrhea received a 10-day blister pack of zinc, if they were not
already taking it for that episode. Every two months, households of
all participants, regardless of study arm, received 2 packets of low-
osmolarity ORS. All medicines were given free of charge.
Distribution of home zinc/ORS was done by village reporters,
women who lived in the village and had minimal health-related
training. Village reporters received a week-long training initially
and refresher trainings every 2 months on treatment of diarrhea in
children, how and when to use zinc and ORS, when mothers
should take their child to the clinic, and were instructed to
emphasize that zinc and/or ORS use was not a substitute for
taking their child to the clinic. Special emphasis was given in
training the village reporters that zinc was to treat only diarrhea,
and if a child had other symptoms, such as fever or cough, they
might also need an antimalarial or antibiotic at the clinic. [20] At
each bi-monthly home visit, the village reporters re-educated
mothers on proper use of zinc and ORS. Village reporters, who
were unblinded to study arm, delivered zinc and/or OR were
every 2 months, regardless of whether the previous supply had
been used.
Although part of the MOH essential drug list, zinc was not
available in MOH-run health facilities at the start of this study in
February 2008. Nor was zinc available in the private sector in
rural Kenya at that time. Therefore, zinc was only available to
children with diarrhea presenting to Lwak Hospital. By late 2008,
zinc had started to become available in MOH-run health facilities
in the study area, although stock-outs were frequent.
Participants who had a diarrhea episode reported at the regular
bi-weekly HMS visits were visited again seven days later to inquire
about ongoing illness, medication use, and any adverse events.
Laboratory
To establish baseline zinc levels in the study area we randomly
selected eight children from each of 33 villages, with the intent to
enroll the first five who were available and consented for each
village, for a goal of 165 children. We measured serum zinc
concentrations, using Flame Atomic Absorption Spectrophotom-
etry, at the KEMRI laboratory in Nairobi. Calibration of
instruments was done using sera with known concentrations
provided by ICDDR-B in Bangladesh. Zinc deficiency in children
was considered as a concentration ,65 mg/dl. [3,21].
Case Definitions
Case definitions for syndromes for HMS and clinic surveillance
are given in Table 1. [15] Definitions for diarrhea, dehydration
and ALRI follow WHO’s Integrated Management of Childhood
Illness guidelines. [22].
Village Randomization
We chose a randomization method that would probabilistically
maintain similar numbers of children in each village category, by
alternating village assignment, after a random starting assignment,
based on an ordered list of villages by population size. Villages
were not matched or stratified based on baseline rates of
morbidity, mortality or health-seeking patterns. Village random-
ization was done at KEMRI/CDC after consenting all initial
participants in December 2007. Village reporters informed
participants of their village group at the time of first home zinc/
ORS distribution in January 2008. Mothers from comparison
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villages could not be given zinc by village reporters since their
group assignment was by their village of residence; all village
reporters were from the villages and knew mothers in their own
village.
Data Analysis
We considered the first 2 months (January–February 2008) a
pilot study, excluding those months from analysis. Therefore, the
study period for analysis was February 2008 to March 2009. We
considered the pre-intervention period as October 2006–Novem-
ber 2007, which was when HMS data were available for all
villages. Pre-intervention period data were included in analyses to
account for baseline differences in disease rates and distance to
clinic between village categories. Pre-intervention data on
medication use were not available.
Because the population of children in the PBIDS villages was
fixed, we calculated what decrease in diarrhea incidence we could
detect with a power of 80% or greater at an alpha of 0.05. We
estimated the PBIDS population of children 2–59 months old to
be approximately 3,000, and assumed a baseline diarrhea
incidence of 3.6 episodes per year. Assuming that there would
be a 5% decrease in diarrhea rates in the comparison villages
during the study period due to zinc use in the clinic, we estimated
that we would have the power to detect a difference of 12% in
rates between zinc and comparison groups, accounting for
correlation of diarrhea events by child using the method described
by Rochon. [23].
Baseline characteristics between children in zinc and compar-
ison villages were compared by chi-square or t-test, controlling for
clustering at the village level. The percentages of episodes of illness
in the zinc and comparison villages that resulted in zinc or other
medication use, or care-seeking outside the home, were compared
using the F-test in SAS PROC GLIMMIX with village as a
random effect to control for clustering; for the analysis of care-
seeking we adjusted for seeking care outside the home for similar
illness episodes in the pre-intervention period. Rates of illness were
compared between children in zinc and comparison villages, both
for those resulting in a sick visit to Lwak Hospital and those
reported during the biweekly HMS visits. For the HMS, rates were
calculated using newly reported episodes divided by the number of
total days from which HMS data were available; due to poor recall
of symptoms we only calculated rates for the day of the home visit
and the three previous days, as we have described before. [15,24]
For the clinic, rates were calculated by using the number of clinic
visits for a syndrome divided by the person-time of residence in the
surveillance area. Children contributed person-time from the date
of their enrollment until the end of the study (March 31, 2009),
their fifth birthday, or their date of outmigration or death. Rate
ratios were calculated between zinc and comparison villages,
adjusting for pre-intervention rates of the syndrome in the child’s
village, distance of the child’s compound to Lwak Hospital, and
the child’s age. For pre-intervention rates, all children in the study
villages aged 2–59 months enrolled in morbidity surveillance were
used, whereas rates during the intervention period were limited to
only those enrolled in the zinc study. Analyses of rates were done
using poisson regression with generalized estimating equations to
control for correlated observations (PROC GENMOD, SAS
version 9.1). A second ‘‘per-treatment’’ analysis was done for clinic
visits, where we included only children who took at least one
course of zinc (intervention villages) or ORS (comparison villages)
during the course of the study. All data analysis was done
unblinded to study arm.
Findings
In total, 1,440 children were enrolled in 16 zinc villages and
1,584 in 17 comparison villages (Figure 1). Over 80% of eligible
children were enrolled at the outset in both groups; however, for
children who were born or in-migrated into the area after the start
of the study, only 36–44% were enrolled due to delays in
registering children into the surveillance system. Of enrolled
children, all were included in the clinic-based analysis, but 17%
were excluded from the household-based analysis since no
household morbidity data was available for these children during
the study period; this was likely due to nobody being at home
during biweekly household visits or temporary relocation of
residences. During the study period, in the zinc and comparison
villages, 96 and 106 children moved out of the study area, 31 and
41 died, and 346 and 431 reached their fifth birthday, respectively.
Zinc and comparison villages were similar in terms of children’s
age, maternal education, socioeconomic status, and crowding
(Table 2). Zinc villages tended to be further from Lwak Hospital
than comparison villages (4.7 vs. 3.4 kilometers, p = 0.07). At
baseline, we collected blood for zinc concentration measurement
Table 1. Case definitions for major infectious disease syndromes from clinic and household morbidity surveillance (HMS) in
Asembo, western Kenya.
Syndrome Clinic definition Household definition
Acute respiratory
infection (ARI)
($1 symptom): cough, difficulty breathing, chest pain, sore throat, sneezing, ear complaints
or runny nose




cough or difficulty breathing with one of the following: elevated respiratory rate for age*
(non-severe pneumonia;) or IMCI danger sign{, lower chest wall indrawing, stridor, or oxygen
saturation ,90% (severe/very severe pneumonia)
cough or difficulty breathing and
rapid respiration for age* or chest
indrawing noted on exam
Diarrhea $3 looser than normal stools in a 24 hour period. Severe defined as IMCI danger sign or
symptom/sign dehydration`




documented axillary temperature $38.0uC without an obvious cause, defined as cough,
difficulty breathing, chest pain, signs of meningitis, or bloody diarrhea (positive
malaria smear is not an exclusion)
report of fever, without evidence of
another infection defined as cough
or difficulty breathing or bloody
diarrhea
*Elevated respiratory rate for age based on WHO Integrated Management of Childhood Illness algorithm [14]; ,2 months, $60 breaths/minute; 2–11 months, $50
breaths/minute; 12–59 months, $40 breaths/minute.
{IMCI danger signs are maternal report of convulsions, inability to drink or breastfeed, or vomiting everything, or on exam lethargy or unconsciousness [22].
`IMCI signs/symptoms of dehydration are the following: sunken eyes, slow skin pinch, restless/irritable behavior, drinking eagerly or not at all [22].
doi:10.1371/journal.pone.0094436.t001
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from 151 children who were enrolled and consented. Of these, 135
(89%) blood samples of adequate volume and quality, the median
zinc concentration was 72.0 mg/dL (IQR 61–88); 32% of children
had low zinc levels (,65 mg/dL). There was no difference between
median zinc concentrations of children in the zinc group (72 mg/
dL) and comparison group (73.0 mg/dL, p = 0.87).
There were 969 7-day follow up visits for diarrheal episodes in
zinc villages and 953 in comparison villages. In zinc villages 6.1%
of children still had diarrhea versus 5.6% in comparison villages
(p = 0.57). Among zinc users, the median number of days that zinc
had been taken was 8.0 in both village groups. Twenty-one
percent of children given zinc had vomited a zinc tablet; 69% of
vomiting episodes were limited to the first zinc dose (no difference
by village group). The median number of ORS sachets used was
2.0.
Based on self-report of the caretaker at the biweekly HMS visit,
in zinc villages 61.2% of all diarrheal episodes were treated with
zinc, compared to 5.4% in the comparison villages (p,0.0001,
Table 3). Similar differences in zinc use were observed for episodes
of diarrhea with fever and with cough. There were no differences
in ORS use for diarrhea between zinc (59.6%) and comparison
villages (58.8%). Diarrheal episodes in zinc villages resulted in less
frequent use of antimalarials and antibiotics (Table 3). Children
with diarrhea and reported fever in zinc villages (approximately
two-thirds of diarrheal episodes) received an antimalarial less
frequently (17.8%) than in comparison villages (23.5%, p = 0.048).
Care-seeking outside the home for diarrhea episodes was similar
between village groups. Among children with fever or cough
without diarrhea, zinc use was low in both zinc and comparison
villages (,0.5%), although care-seeking outside the home was
higher in comparison villages for these non-diarrhea syndromes.
Although rates of clinic visitation due to diarrhea were lower in
the zinc than comparison villages during the intervention period,
this difference was not statistically different after adjustment
(Table 4). Similarly, no significant differences were observed
between zinc and comparison villages for clinic visits for rates of
severe diarrhea, ARI, ALRI, acute febrile illness or malaria
parasitemia (Table 4). We found similar results when limiting the
clinic-based analysis to only those children who took at least one
course of zinc or ORS during the study period (Table 5). There
were also no significant differences in the incidence of reported
diarrhea, diarrhea with fever, severe diarrhea, ARI, or acute
febrile illness at the biweekly household visits (Table 6). However,
children in the zinc villages had 32% fewer reported ALRI
episodes than in comparison villages (adjusted RR 0.68, 95% CI
0.46–0.99). There were no differences between village groups in
hospitalization rates or all-cause mortality (Table 4).
Discussion
We did not observe a community-level impact on diarrhea
incidence in home zinc villages despite increased zinc use. There
are several potential reasons. First, it is possible that zinc use does
not prevent future diarrhea episodes in this setting; most studies on
Figure 1. Trial profile. Village randomization and number of children enrolled at the initial enrollment in December 2007 and during the ongoing
enrollment during the study period from February 2008–March 2009. Children and person-time contribution given for the analysis of clinic-based
surveillance and household morbidity surveillance – see methods. PBIDS = Population-based Infectious Disease Surveillance.
doi:10.1371/journal.pone.0094436.g001
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the preventive effect of zinc on diarrhea occurred in South Asia
and the epidemiology of diarrhea disease differs in Africa.
[2,7,8,25] Second, perhaps not enough children received zinc in
the community to precipitate a measureable decrease in commu-
nity-level incidence. We were not able to enroll as many children
as we anticipated, particularly for the household-level morbidity
analysis, and so it is possible we were unpowered to detect a
difference. We did not, however, see reduced diarrhea rates when
restricting the analysis to only children who took zinc. Third,
possibly we were unable to detect a real decrease in diarrhea
incidence due to limitations in our study design (e.g. baseline
differences between village groups), which we were unable to fully
adjust for. Moreover, biases in surveillance could have masked an
impact on incidence; children given zinc at home might have had
reduced health-seeking at clinic because of less perceived need for
medication, or caretakers who gave zinc might have been more
likely to recall and report diarrheal episodes at the home visits.
Although we did not observe a difference in diarrhea rates, we did
see marginally less ALRI in the zinc villages reported at the
household, but not at the clinic; zinc treatment for diarrhea has
been shown to prevent subsequent ALRI in India. [8].
While this study did not provide evidence for a community-level
preventative impact of home zinc use, we did show that by
providing zinc in the home children with diarrhea were much
more likely to receive zinc treatment than when zinc was only
available in the health facility. Moreover, having ORS available at
home likely resulted in higher uptake of ORS for diarrhea
treatment than occurred historically in this area. [9,26,27] In
much of rural Africa, such as western Kenya, most children with
diarrhea are not taken to health facilities. [12] We have previously
shown in our area that only 36% of children with diarrhea seek
care at a health facility. [26] Of note, an additional 50% of
children sought care at sources besides licensed health facilities,
suggesting that making zinc available through drug sellers,
community health workers, or private providers could also
increase the number of diarrheal episodes treated with zinc.
Our study demonstrated that caretakers of children can be
educated to use zinc appropriately at home. In our study, very few
caretakers used zinc to treat illnesses without diarrhea. Misuse of
zinc has been raised as a concern whereby mothers might
substitute one drug, particularly a free one, for other necessary
drugs, like antimalarials, which have an extra real or opportunity
cost to acquire. [20] Yet, our study did show some potential
cautionary information similar to what was shown in a commu-
nity-based zinc program in Mali in that children with diarrhea
with fever tended to be less likely to receive antimalarial
medications. [20] Although it is possible that fever could be part
of the diarrhea episode, in an endemic malaria area, such as rural
western Kenya, all episodes of fever merit either empiric malaria
treatment or a reliable diagnostic test to rule out malaria. [28] This
speaks to the need for ongoing education of caretakers, or
combined home treatment of diarrhea and malaria.
To achieve maximum impact of zinc, we chose to provide zinc
to caretakers in the home for several reasons. First, rural western
Kenya did not have a well-established system of CHWs at the time
of the study, as in other settings in Africa or south Asia. [7,8,20]
Second, zinc was not yet available in public or private facilities and
was virtually unknown in the community as a treatment for
diarrhea. In such a context, we felt that to design a study where
zinc was provided to local drug sellers and shops and expect
mothers to purchase this new and unknown drug would not result
in high levels of zinc usage, even at a minimal price. Third, zinc,
along with ORS, is a good candidate for home treatment as it is
inexpensive, easy-to-use, and has a low adverse event profile. [5]
Mothers already commonly treat children’s illnesses at home on
their own volition in many parts of Africa. [13,20,26] Although the
design we used to deliver zinc and ORS at home is likely not
scalable, with the advent of community-based health approaches
like in Kenya, alternative strategies, including cost-effectiveness
analyses, of delivery of home zinc and ORS to treat diarrhea need
to be explored.
Although our study shows safe and proper use of zinc by
caretakers at home, alternate approaches to increasing zinc use
outside the clinic are possible. Treatment with zinc could be
undertaken by community health workers, as in other places.
[7,8,10] Moreover, zinc could be made more accessible to
caretakers if it was available through non-facility sources of drugs,
which in rural Africa could include CHWs through the iCCM
strategy [29,30] or drug sellers through local shops and
pharmacies, as has been done for effective antimalarial treatment
in many parts of Africa. [31].
Table 2. Baseline characteristics for participants in home zinc and comparison villages, western Kenya, February 2008–March 2009.
Characteristic Home zinc Comparison P value*
N 1440 1584
Age in months (median) 28.2 27.9 0.58
Age categories, n (%)
2–5 months 202 (14) 246 (16) 0.31
6–11 mo 139 (10) 147 (9)
12–23 mo 278 (19) 279 (18)
24–59 mo 821 (57) 912 (58)
Male, n (%) 732 (51) 772 (49) 0.38
Maternal education beyond primary 291 (20) 322 (20) 0.89
Poorer households{ 345 (29) 379 (28) 0.79
Distance from residence to Lwak (median meters) 4728 3351 0.07
# children ,5 years in household (median) 2.0 2.0 0.36
*p value controls for cluster design by village.
{Poorer household is defined as the lowest two quintiles using multiple component analysis.
doi:10.1371/journal.pone.0094436.t002
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Our study had several other potential limitations. First, our
study was not designed to evaluate the impact of zinc the duration
or severity of diarrhea episodes. Because zinc use has been shown
to reduce diarrhea duration in multiple settings in several meta-
analyses, we expected that in our setting, where approximately
one-third of children were zinc-deficient, zinc would be effective in
reducing diarrhea duration and did not need to be studied. [1,5,6]
Second, zinc was only available for treatment in Lwak Hospital
and not other area clinics during most of the study period.
Therefore, zinc use was lower than in a setting where all clinics
have zinc available. Nonetheless, if we doubled the percentage of
diarrhea episodes treated with zinc to account for health-seeking at
other area clinics, zinc use would still have been substantially lower
(10.8%) among children receiving zinc in the clinics only
compared with the children receiving zinc at home (61.2%).
[19] Third, because we did not match or stratify villages on
incidence of diarrhea or health-seeking at the time of village
randomization, there were some baseline differences between
village groups. Although we did adjust for baseline rates in our
analysis of disease incidence, it is possible that residual confound-
ing due to baseline differences by village group remained.
Moreover, we did not have baseline rates of antimicrobial use,
so could not adjust for baseline differences in the analysis of the
impact of zinc on antimicrobial use, including antimalarials.
Fourth, our findings on zinc’s impact on prevention might have
been biased towards the null by including children younger than
six months of age. There is no evidence that zinc use among
children ,6 months of age shortens duration of diarrhea episodes
or prevents subsequent episodes [5,32–34].
Since we undertook this study, the Kenya MOH has fully
adopted zinc as part of the essential drug kit available in health
facilities. Although we did not show a decrease in community
Table 3. Effect of intervention on drug use and healthcare use for various disease syndromes during the intervention period from
household morbidity surveillance (HMS), western Kenya, February 2008–March 2009.
Home zinc N (%{) Comparison N (%{) P value*
All diarrhea (n) 1707 1700
Zinc 1045 (61.2) 92 (5.4) ,.0001"
ORS 1018 (59.6) 999 (58.8) .62
Antimalarial 190 (11.1) 272 (16.0) .006
Antibiotic 291 (17.1) 383 (22.5) .018
Sought care{ 531 (31.2) 542 (31.9) .22
Diarrhea+fever (n) 1043 1133
Zinc 624 (59.8) 72 (6.4) ,.0001
ORS 629 (60.3) 655 (57.8) .31
Antimalarial 186 (17.8) 266 (23.5) .048
Antibiotic 253 (24.3) 322 (28.4) .22
Sought care{ 380 (36.5) 412 (36.4) .26
Diarrhea+cough (n) 701 716
Zinc 415 (59.2) 45 (6.3) ,.0001
ORS 426 (60.8) 400 (55.9) .11
Antimalarial 122 (17.4) 150 (21.0) .28
Antibiotic 192 (27.4) 226 (31.6) .21
Sought care{ 253 (36.1) 255 (35.7) .61
Fever without diarrhea (n) 6188 6693
Zinc 13 (0.2) 2 (0.03) N/A
ORS 25 (0.4) 37 (0.6) .33
Antimalarial 1510 (24.4) 1701 (25.4) .81
Antibiotic 1187 (19.2) 1221 (18.2) .70
Sought care{ 2509 (40.6) 3023 (45.3) .017
Cough without diarrhea (n) 5412 5170
Zinc 10 (0.2) 1 (0.02) .039
ORS 12 (0.2) 22 (0.4) .31
Antimalarial 868 (16.0) 883 (17.1) .78
Antibiotic 1396 (25.8) 1368 (26.5) .48
Sought care{ 1999 (36.9) 2089 (40.5) .019
*p-value calculation includes a random effect variable for village, and adjusts for pre-intervention rates of seeking care outside the home by village - F-test in SAS PROC
GLIMMIX.
{% given in table is the % of biweekly household visits with illness that resulted in medication use or care-seeking outside the home. Denominator for sought care was
slightly lower than for medication use due to some missing data for that variable.
"For primary outcome, intracluster correlation (ICC) = 0.030.
doi:10.1371/journal.pone.0094436.t003
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incidence of diarrhea when zinc was available in the home, we did
show that far more children with diarrhea in rural Kenya, and
perhaps most areas of rural Africa, would likely be treated with
zinc for diarrhea if zinc were either available in the home or at the
community level, rather than in only health facilities. Adequate
education, training and monitoring will be essential in adopting
Table 4. Effect of home zinc on rate of sick visits to Lwak clinic, hospitalization, and mortality, western Kenya, from February 2008–
March 2009, controlling for baseline rates of morbidity in home zinc and comparison villages.
Pre-intervention* Intervention period{ Adjusted RR` (CI 95%)
Home zinc Comparison Home zinc Comparison
Person-years observed 2001 2245 1214 1335
Diarrhea 0.098 0.118 0.146 0.184 1.05 [0.81–1.37]"
Diarrhea plus reported fever 0.089 0.102 0.138 0.160 1.09 [0.83–1.43]
Diarrhea and malaria 0.025 0.023 0.072 0.090 1.05 [0.74–1.49]
Severe diarrhea 0.040 0.046 0.059 0.059 1.17 [0.79–1.76]
Diarrhea hospitalization 0.027 0.034 0.037 0.051 0.87 [0.56–1.36)
Acute Respiratory Illness 0.406 0.464 0.830 0.904 1.16 [0.98–1.37]
ALRI 0.053 0.065 0.083 0.095 1.06 [0.78–1.45]
ALRI hospitalization 0.035 0.049 0.041 0.055 0.91 [0.59–1.39]
Acute febrile illness 0.030 0.049 0.145 0.162 1.30 [0.99–1.69]
Malaria (Blood smear+) 0.033 0.040 0.530 0.611 1.19 [0.99–1.44]
All-cause hospitalization 0.093 0.126 0.161 0.195 1.06 [0.82–1.38]
Mortality 0.023 0.029 0.024 0.029 0.83 [0.49–1.40]
Intention-to-treat analysis includes all enrolled children. Rates are given as episodes per person-year.
*Pre-intervention period was October 2006 to November 2007.
{While pre-intervention includes all children in the village of appropriate age, the intervention period only includes those enrolled in the home zinc study.
`Rate ratio is comparing rates between home zinc and comparison groups during the intervention period, adjusted for pre-intervention rates of same syndrome in the
child’s village, distance of child’s compound to Lwak Hospital and child’s age.
"For primary outcome, intracluster correlation (ICC) = 0.027.
doi:10.1371/journal.pone.0094436.t004
Table 5. Effect of home zinc on rate of sick visits to Lwak clinic, hospitalization, and mortality, western Kenya, from February 2008–
March 2009, controlling for baseline rates of morbidity in home zinc and comparison villages.
Pre-intervention* Intervention period{ Adjusted RR` (CI 95%)
Home zinc Comparison Home zinc Comparison
Person-years observed 2001 2245 598 625
Diarrhea 0.098 0.118 0.22 0.31 0.99 [0.73–1.33]
Diarrhea plus reported fever 0.089 0.102 0.21 0.27 1.02 [0.76–1.39]
Diarrhea and malaria 0.025 0.023 0.10 0.14 0.87 [0.57–1.34]
Severe diarrhea 0.040 0.046 0.10 0.11 1.14 [0.72–1.79]
Diarrhea hospitalization 0.027 0.034 0.06 0.09 0.82 [0.49–1.36)
Acute Respiratory Illness 0.406 0.464 0.86 1.18 0.93 [0.76–1.13]
ALRI 0.053 0.065 0.11 0.15 0.95 [0.65–1.40]
ALRI hospitalization 0.035 0.049 0.06 0.09 0.93 [0.56–1.53]
Acute febrile illness 0.030 0.049 0.16 0.22 1.20 [0.84–1.71]
Malaria (Blood smear+) 0.033 0.040 0.49 0.77 0.89 [0.70–1.12]
All-cause hospitalization 0.093 0.126 0.17 0.29 0.79 [0.57–1.09]
Mortality 0.023 0.029 0.02 0.04 0.69 [0.34–1.41]
Per-treatment analysis includes only children who received at least one course of zinc in home zinc villages and one course of ORS in comparison villages. Rates are
given as episodes per person-year.
*Pre-intervention period was October 2006 to November 2007.
{While pre-intervention includes all children in the village of appropriate age, the intervention period only includes those enrolled in the home zinc study who took one
course of recommended treatment for diarrhea.
`Rate ratio is comparing rates between home zinc and comparison groups during the intervention period, adjusted for pre-intervention rates of same syndrome in the
child’s village, distance of child’s compound to Lwak Hospital and child’s age.
doi:10.1371/journal.pone.0094436.t005
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such a strategy. Assuming zinc has the same treatment and
preventive impact in rural Africa as elsewhere, greater zinc use
would translate into a beneficial public health impact.
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